GLP-1 Market
LLY $1251.61 ▲ +3.5% NVO $39.22 ▲ +2.9% PFE $29.44 ▲ +0.8% VKTX $27.37 ▲ +7.5% KLRA $11.71 ▲ +9.0% GPCR $22.19 ▲ +1.4% RHHBY $56.78 ▲ +2.0%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

DA-302168S

DA-302168S

Company
Chendu DIAO Pharmaceutical Group CO., LTD.
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
1 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

1 recruiting study currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Oct 16, 2026

Find a Clinical Trial Near Me

See recruiting studies for DA-302168S and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT07629544

    A Study of DA-302168S in Participants With Overweight/Obesity

    Not yet reported Chendu DIAO Pharmaceutical Group CO., LTD. 840 participants Est. completion 2027-10-19 1 site
    Other conditions: Overweight and Obesity
    View official trial listing →
  • Completed NCT NCT06534320

    Safety, Tolerability and Pharmacokinetic Characteristics Evaluation of DA-302168S Tablets

    Not yet reported Chendu DIAO Pharmaceutical Group CO., LTD. 50 participants Est. completion 2024-12-31 1 site Stand-alone
    Other conditions: Overweight and Obesity
    View official trial listing →
  • Completed NCT NCT06534346

    The Food Effect on Pharmacokinetics of DA-302168S

    Not yet reported Chendu DIAO Pharmaceutical Group CO., LTD. 16 participants Est. completion 2024-08-03 1 site Stand-alone
    Other conditions: Overweight and Obesity
    View official trial listing →
  • Completed NCT NCT06541730

    A Study Evulating DA-302168S Tablets in Overweight/Obese Subjects

    Not yet reported Chendu DIAO Pharmaceutical Group CO., LTD. 48 participants Est. completion 2025-01-30 1 site Stand-alone
    Other conditions: Overweight and Obesity
    View official trial listing →
  • Completed NCT NCT06953063

    A Study to Evaluate the Efficacy and Safety of DA-302168S Tablets in Overweight/Obese Subjects

    Not yet reported Chendu DIAO Pharmaceutical Group CO., LTD. 250 participants Est. completion 2025-12-15 1 site Stand-alone
    Other conditions: Overweight and Obesity
    View official trial listing →
  • Not yet recruiting NCT NCT07755150

    A Study to Evaluate the Efficacy and Safety of DA-302168S Tablets in Subjects With Type 2 Diabetes

    Not yet reported Chendu DIAO Pharmaceutical Group CO., LTD. 272 participants Est. completion 2027-10-20 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Not yet recruiting NCT NCT07857265

    Mass Balance Study of [14C]DA-302168S in Healthy Chinese Adult Male Participants

    Not yet reported Chendu DIAO Pharmaceutical Group CO., LTD. 10 participants Est. completion 2026-12-20 Stand-alone
    Other conditions: Healthy Adult Subjects
    View official trial listing →
  • Not yet recruiting NCT NCT07877038

    Pharmacokinetics, Safety, and Tolerability of DA-302168S Tablets in Participants With Hepatic Impairment and Normal Hepatic Function

    Not yet reported Chendu DIAO Pharmaceutical Group CO., LTD. 32 participants Est. completion 2027-04-07 Stand-alone
    Type 2 diabetes Other conditions: Obesity, Overweight
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.